Saturday 17 October 2026 Export STOK’s income statement to Excel — free account

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.

24.17 0.44 −1.79%

Follow STOK

Alert me

Market cap: $1.6B
P/E: 0.0×
Fwd P/E: −9.1×
Dividend yield: —
F-score: 5/9
Altman Z: 16.42
Beneish M: 0.76
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 8.77

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	8	—	—	9	1	1	2	1	4	—	2

Insider Ownership 18.98%

Capital & Financial Ratios $m

Market Cap 1,590.00

Revenue 27.59

Net Income (207.90)

Free Cash Flow (180.68)

Net Debt (292.82)

Current Ratio 7.69

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (9.13)

P/S ratio 57.84

P/B ratio 4.62

Past 5Y EPS Growth —

This Y EPS Growth (2,936.76%)

Next Y EPS Growth 1.42%

Next Y revenue growth (82.64%)

Next 5Y EPS Growth (24.20%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 79.60%

10-year low 10-year high

P/B against its own 10 years 69.69%

10-year low 10-year high

EV/Sales against its own 10 years 80.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	201	217	285	293
Receivables	0	2	8	9
Inventory	—	—	—	—
Other	3	2	4	6
	215	233	306	323

	2023	2024	2025	Q'26
Payables	2	2	5	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	31	40	58	42

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	145.89%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	4.26%	24.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	9	—	—	—
’25	159	14	11	1	184
’24	4	5	5	23	37
’23	5	(2)	3	3	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(61)	(57)	—	—	—
’25	132	(25)	(30)	(30)	46
’24	(25)	(17)	(22)	(23)	(87)
’23	(21)	(22)	(17)	(21)	(81)
’22	32	(20)	(22)	(22)	(32)
’21	(20)	(16)	(15)	(16)	(67)
’20	(11)	(10)	(11)	(11)	(42)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(61)	(59)	—	—	—
’25	132	(26)	(30)	(31)	45
’24	(25)	(18)	(22)	(23)	(87)
’23	(22)	(23)	(18)	(21)	(83)
’22	32	(21)	(24)	(23)	(36)
’21	(20)	(16)	(15)	(16)	(68)
’20	(11)	(10)	(11)	(11)	(43)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.79)	(0.93)	—	—	—
’25	1.90	(0.40)	(0.65)	(0.97)	(0.12)
’24	(0.57)	(0.46)	(0.47)	(0.18)	(1.65)
’23	(0.53)	(0.69)	(0.55)	(0.60)	(2.38)
’22	(0.66)	(0.63)	(0.66)	(0.65)	(2.60)
’21	(0.46)	(0.60)	(0.61)	(0.66)	(2.34)
’20	(0.34)	(0.39)	(0.41)	(0.42)	(1.56)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	19.21	15.82	17.76	6.88	3.35	4.09	5.35	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	39.04	64.54	71.58	26.60	14.00	17.58	38.69
People
People	Employees	—	—	44	56	79	102	117	110	128	170
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.11	0.08	0.29	1.08
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	12	9	37	184
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
	EBT	—	(6)	(13)	(32)	(52)	(86)	(101)	(105)	(89)	(7)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	(814.73)	(1,192.47)	(243.42)	(3.73)
	Net income	—	0	(13)	(32)	(52)	(86)	(101)	(105)	(89)	(7)
	Depreciation	—	0	0	0	1	1	1	2	1	1
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.32	0.20	0.68	3.11
	Earnings	—	(0.17)	(17.65)	(1.80)	(1.56)	(2.34)	(2.60)	(2.38)	(1.65)	(0.12)
	Cash flow	—	(0.16)	(15.46)	(1.73)	(1.26)	(1.82)	(0.82)	(1.84)	(1.61)	0.77
	Capex	—	0.00	(1.30)	(0.09)	(0.03)	(0.03)	(0.10)	(0.04)	0.00	(0.01)
	Free cash flow	—	(0.16)	(16.76)	(1.82)	(1.29)	(1.85)	(0.92)	(1.88)	(1.61)	0.76
	Book value	—	(0.04)	148.13	12.49	8.54	5.93	4.75	3.63	4.24	5.95
	Shares, m	—	33	1	18	33	37	39	44	54	59
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	28.50	29.36	16.30	10.19
	P/B	—	—	—	—	—	—	1.91	1.62	2.60	5.33
	EV/Sales	—	—	—	—	—	—	9.99	6.43	10.36	8.65
	EV/FCF	—	—	—	—	—	—	(3.46)	(0.68)	(4.35)	35.51
Cash, $m
Cash, $m	Operating cash flow	—	(5)	(11)	(31)	(42)	(67)	(32)	(81)	(87)	46
	Capex	—	0	(1)	(2)	(1)	(1)	(4)	(2)	0	(1)
	Free cash flow	—	(5)	(12)	(33)	(43)	(68)	(36)	(83)	(87)	45
Balance, $m
Balance, $m	Working capital	—	(2)	104	222	283	212	213	185	193	248
	Total debt	—	3	—	—	0	5	5	—	—	—
	Net debt	—	1	(105)	(222)	(287)	(220)	(230)	(201)	(217)	(285)
	Shareholders’ equity	—	(1)	105	224	286	218	185	160	229	352
Returns, %
Returns, %	ROA	—	(10.11)	(23.29)	(19.22)	(19.84)	(31.97)	(40.84)	(43.23)	(35.60)	(2.00)
	ROIC	—	0.00	0.00	(1,139.44)	0.00	0.00	0.00	0.00	(525.92)	(19.12)
	ROE	—	(10.71)	(24.13)	(19.62)	(20.47)	(34.06)	(50.20)	(60.80)	(45.80)	(2.37)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZBIO Zenas BioPharma, Inc.	$1.7B	— (loss-making)	— (loss-making)	—	n/m	−37.12% (below 0%: shrinking)	100.00%	(10,765.90%)	Compare
OCUL Ocular Therapeutix, Inc.	$1.6B	— (loss-making)	— (loss-making)	+0.12% (above 0%: growing)	n/m	−25.35% (below 0%: shrinking)	85.08%	(609.34%)	Compare
STOK Stoke Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−32.51% (below 0%: shrinking)	n/m	−128.97% (below 0%: shrinking)	100.00%	(701.65%)
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
Median of peers	$1.6B	—	—	−43.24%	—	−31.23%	100.00%	(751.53%)

All 614 Biotechnology stocks →

Stoke Therapeutics, Inc. (STOK) key facts

Concern: Stoke Therapeutics, Inc. reported a net loss of $6.9 million, or a loss of $0.12 per share, for fiscal 2025.
Strength: Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.
Stoke Therapeutics, Inc. (STOK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, STOK traded at $24.17, a market capitalization of $1.6 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 57.8× sales.
Return on equity was −2.37% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 16.42 (safe zone) for fiscal 2025.